About this trial
The goal of this randomized clinical trial is to assess whether β-TCP (Beta-Tricalcium Phosphate) improves alveolar ridge preservation (ARP) in patients who need tooth extraction. The main question it aims to answer is whether using β-TCP for alveolar ridge preservation has a positive effect on bone volume compared with natural healing.
The main questions it aims to answer are:
Does β-TCP improve ridge preservation compared with natural healing?
Researchers will compare β-TCP grafted sockets to natural healing sockets to see if β-TCP better preserves ridge volume.
Participants will:
Have a tooth indicated for extraction.
Be assigned to either β-TCP or natural healing.
Undergo CBCT (Cone Beam Computed Tomography) and intra-oral scanning after extraction and after six months of healing to measure horizontal and vertical resorption and bone density.
Eligibility criteria
Qualifiers
18 years or older
Acceptance of informed consent
Type 1 or 2 extraction sockets (Elian et al. 2007)
Disqualifiers
Presence of active infection or severe inflammation in the intervention zone
Relevant medical history that contraindicates implant surgery
Patients with poor oral hygiene (full-mouth plaque score and full-mouth bleeding score >15%) and lack of motivation
Uncontrolled diabetes (reported levels of glycated haemoglobin exceeding 7%)
Trial design
Treatments tested in this trial
- Neocement Inject P® (Beta-Tricalcium Phosphate)